OpenEvidence, a specialized artificial intelligence platform for medical professionals, has reportedly closed a $200 million funding round, elevating its valuation to $6 billion. The New York Times first reported the development on October 20, 2025.
This latest financing follows a $210 million round just three months prior, which had valued the startup at $3.5 billion. The rapid increase in valuation underscores significant investor interest in sector-specific AI applications, according to market observers.
The OpenEvidence platform, established in 2022, is designed to assist doctors and nurses by providing rapid answers to medical inquiries, drawing from a vast corpus of medical knowledge. Its training data includes content from prominent medical journals such as JAMA and The New England Journal of Medicine. Verified medical professionals can access the tool at no cost, with the service supported by advertising revenue.
The company has experienced substantial growth since its inception. Reports indicate that OpenEvidence's monthly clinical consultations have nearly doubled since July, reaching approximately 15 million. This expansion reflects the adoption of AI tools within the healthcare sector for knowledge synthesis and clinical decision support.
Google Ventures led the recent funding round. Participating investors included Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. These investments signal continued confidence in the expansion of AI technologies into specialized industrial domains, particularly those requiring extensive data processing and rapid information retrieval.
As of this report, OpenEvidence has not issued an official statement regarding the funding.
